Cheol Kyu Hwang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cheol Kyu Hwang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Horace H. Loh
University of Minnesota Medical School
10 shared publications- Ping-Yee Law
Department of Pharmacology, University of Minnesota, Minneapolis, USA
8 shared publications Chun Sung Kim
5 shared publicationsLi-Na Wei
University of Minnesota Medical School
5 shared publicationsYadav Wagley
University of Minnesota Medical School
4 shared publicationsDo Kyung Kim
Department of Pharmacology University of Minnesota Medical School Minneapolis Minnesota USA
3 shared publications
Latest Publications
- 15 September 2014
- Published by Springer Nature
- Vol. 1230, 39-51
Analysis of Epigenetic Mechanisms Regulating Opioid Receptor Gene Transcription
Opioid drugs are generally used for moderate and severe pain reductions which act through opioid receptors. Studies on transcriptional regulation of opioid receptors are still invaluable because not only transcription is the first step to produce protein products in cells, but the receptor transcription levels also affect the pain reduction by opioids, as observed in studies of heterozygous opioid receptor knockout mice. There are growing evidences that epigenetic regulation has played significant roles in transcriptional regulation of genes, including opioid receptors. In general, epigenetic mechanisms include three main regulatory factors: DNA methylation, chromatin modification, and noncoding RNAs (such as microRNA). From previous studies of ours and others on opioid receptors, those epigenetic factors were clearly involved in regulating opioid receptor expression in vivo and in vitro. In this chapter, among those three techniques we describe more details of DNA methylation methods because of emerging concepts of DNA methylation with the recent discovery of 5-hydroxymethylcytosine converting enzyme, TET1. Another analytical method of the epigenetic factors, chromatin modification, will be described briefly and information of analyzing noncoding RNAs is briefly mentioned in Subheading 1.
- 15 September 2014
- Published by Springer Nature
- Vol. 1230, 39-51
Analysis of Epigenetic Mechanisms Regulating Opioid Receptor Gene Transcription
Opioid drugs are generally used for moderate and severe pain reductions which act through opioid receptors. Studies on transcriptional regulation of opioid receptors are still invaluable because not only transcription is the first step to produce protein products in cells, but the receptor transcription levels also affect the pain reduction by opioids, as observed in studies of heterozygous opioid receptor knockout mice. There are growing evidences that epigenetic regulation has played significant roles in transcriptional regulation of genes, including opioid receptors. In general, epigenetic mechanisms include three main regulatory factors: DNA methylation, chromatin modification, and noncoding RNAs (such as microRNA). From previous studies of ours and others on opioid receptors, those epigenetic factors were clearly involved in regulating opioid receptor expression in vivo and in vitro. In this chapter, among those three techniques we describe more details of DNA methylation methods because of emerging concepts of DNA methylation with the recent discovery of 5-hydroxymethylcytosine converting enzyme, TET1. Another analytical method of the epigenetic factors, chromatin modification, will be described briefly and information of analyzing noncoding RNAs is briefly mentioned in Subheading 1.
- Open Access
- 19 October 2012
- Published by Wiley in The FASEB Journal
- Vol. 27 (2) , 522-535
MicroRNA 339 down‐regulates μ‐opioid receptor at the post‐transcriptional level in response to opioid treatment
μ‐Opioid receptor (MOR) level is directly related to the function of opioid drugs, such as morphine and fentanyl. Although agonist treatment generally does not affect transcription of mor , previous studies suggest that morphine can affect the translation efficiency of MOR transcript via microRNAs (miRNAs). On the basis of miRNA microarray analyses of the hippocampal total RNA isolated from mice chronically treated with μ‐opioid agonists, we found a miRNA (miR‐339‐3p) that was consistently and specifically increased by morphine (2‐fold) and by fentanyl (3.8‐fold). miR‐339‐3p bound to the MOR 3′‐UTR and specifically suppressed reporter activity. Suppression was blunted by adding miR‐339‐3p inhibitor or mutating the miR‐339‐3p target site. In cells endogenously expressing MOR, miR‐339‐3p inhibited the production of MOR protein by destabilizing MOR mRNA. Up‐regulation of miR‐339‐3p by fentanyl (EC 50 =0.75 nM) resulted from an increase in primary miRNA transcript. Mapping of the miR‐339‐3p primary RNA and its promoter revealed that the primary miR‐339‐3p was embedded in a noncoding 3′‐UTR region of an unknown host gene and was coregulated by the host promoter. The identified promoter was activated by opioid agonist treatment (10 nM fentanyl or 10 μM morphine), a specific effect blocked by the opioid antagonist naloxone (10 μM). Taken together, these results suggest that miR‐339‐3p may serve as a negative feedback modulator of MOR signals by regulating intracellular MOR biosynthesis.—Wu, Q., Hwang, C. K., Zheng, H., Wagley, Y., Lin, H.‐Y., Kim, D. K., Law, P.‐Y., Loh, H. H., Wei, L.‐N. MicroRNA 339 downregulates mu opioid receptor at the post‐transcriptional level in response to opioid treatment. FASEB J. 27, 522–535 (2013). www.fasebj.org
- 19 October 2012
- Published by Wiley in The FASEB Journal
- Vol. 27 (2) , 522-535
Open AccessMicroRNA 339 down‐regulates μ‐opioid receptor at the post‐transcriptional level in response to opioid treatment
μ‐Opioid receptor (MOR) level is directly related to the function of opioid drugs, such as morphine and fentanyl. Although agonist treatment generally does not affect transcription of mor , previous studies suggest that morphine can affect the translation efficiency of MOR transcript via microRNAs (miRNAs). On the basis of miRNA microarray analyses of the hippocampal total RNA isolated from mice chronically treated with μ‐opioid agonists, we found a miRNA (miR‐339‐3p) that was consistently and specifically increased by morphine (2‐fold) and by fentanyl (3.8‐fold). miR‐339‐3p bound to the MOR 3′‐UTR and specifically suppressed reporter activity. Suppression was blunted by adding miR‐339‐3p inhibitor or mutating the miR‐339‐3p target site. In cells endogenously expressing MOR, miR‐339‐3p inhibited the production of MOR protein by destabilizing MOR mRNA. Up‐regulation of miR‐339‐3p by fentanyl (EC 50 =0.75 nM) resulted from an increase in primary miRNA transcript. Mapping of the miR‐339‐3p primary RNA and its promoter revealed that the primary miR‐339‐3p was embedded in a noncoding 3′‐UTR region of an unknown host gene and was coregulated by the host promoter. The identified promoter was activated by opioid agonist treatment (10 nM fentanyl or 10 μM morphine), a specific effect blocked by the opioid antagonist naloxone (10 μM). Taken together, these results suggest that miR‐339‐3p may serve as a negative feedback modulator of MOR signals by regulating intracellular MOR biosynthesis.—Wu, Q., Hwang, C. K., Zheng, H., Wagley, Y., Lin, H.‐Y., Kim, D. K., Law, P.‐Y., Loh, H. H., Wei, L.‐N. MicroRNA 339 downregulates mu opioid receptor at the post‐transcriptional level in response to opioid treatment. FASEB J. 27, 522–535 (2013). www.fasebj.org
- 9 November 2011
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 7 (4) , 808-819
MicroRNAs in Opioid Pharmacology
MicroRNAs (miRNA), a class of ~22-nucleotide RNA molecules, are important gene regulators that bind to the target sites of mRNAs to inhibit the gene expressions either through translational inhibition or mRNA destabilization. There are growing evidences that miRNAs have played several regulatory roles in opioid pharmacology. Like other research fields such as cancer biology, the area where numerous miRNAs are found to be involved in gene regulation, we assume that in opioid studies including research fields of drug additions and opioid receptor regulation, there may be more miRNAs waiting to be discovered. This review will summarize our current knowledge of miRNA functions on opioids biology and briefly describe future research directions of miRNAs related to opioids.
- 9 November 2011
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 7 (4) , 808-819
MicroRNAs in Opioid Pharmacology
MicroRNAs (miRNA), a class of ~22-nucleotide RNA molecules, are important gene regulators that bind to the target sites of mRNAs to inhibit the gene expressions either through translational inhibition or mRNA destabilization. There are growing evidences that miRNAs have played several regulatory roles in opioid pharmacology. Like other research fields such as cancer biology, the area where numerous miRNAs are found to be involved in gene regulation, we assume that in opioid studies including research fields of drug additions and opioid receptor regulation, there may be more miRNAs waiting to be discovered. This review will summarize our current knowledge of miRNA functions on opioids biology and briefly describe future research directions of miRNAs related to opioids.
- 7 June 2011
- Published by Springer Nature
- p. 49-69
Regulation of the Transcription of G Protein-Coupled Receptor Genes
- 7 June 2011
- Published by Springer Nature
- p. 49-69
Regulation of the Transcription of G Protein-Coupled Receptor Genes
- Open Access
- 27 December 2010
- Published by Wiley in Journal of Neurochemistry
- Vol. 116 (6) , 1077-1087
p38 Mitogen‐activated protein kinase and PI3‐kinase are involved in up‐regulation of mu opioid receptor transcription induced by cycloheximide
J. Neurochem. (2011)116, 1077–1087. Despite several decades of efforts to develop safer, efficacious, and non‐addictive opioids for pain treatment, morphine remains the most valuable painkiller in contemporary medicine. Morphine and endogenous mu opioid peptides exert their pharmacological actions mainly through the mu opioid receptor (MOR). Analgesic effects of opioids in animals are dependent on the MOR expression levels, as demonstrated by studies of MOR‐knockout mice (homo/heterozygotes) and MOR‐less expressing mice. Surprisingly, in the course of our investigation to understand the mechanisms involved in the regulation of MOR gene expression, cycloheximide (CHX), a known protein synthesis inhibitor, markedly induced accumulation of MOR mRNAs in both MOR‐negative and ‐positive cells. This induction was blocked by inhibitors of phosphoinositide 3‐kinase (PI3‐K) and p38 MAPK, but not by a p42/44 MAPK inhibitor.In vitro, CHX was found to activate the MOR promoter and this activation was suppressed by inhibition of PI3‐K. The transcriptional activator Sox18 was recruited to the MOR promoter in CHX‐treated cells and this recruitment was also inhibited by the PI3‐K and p38 MAPK inhibitors, Ly294002 and SB203580, respectively. Consistently, acetylation of histone H3 and induction of H3‐K4 methylation were detected while reductions of histone deacetylase 2 binding and H3‐K9 methylation were observed on the promoter. Furthermore, the MOR mRNA accumulation was almost completely inhibited in the presence of actinomycin‐D, indicating that this effect occurs mainly through activation of the transcriptional machinery. These observations suggest that CHX directly induces MOR gene transcription by recruiting the active transcription factor Sox18 to the MOR promoter through PI3‐ and/or p38 MAPK pathways.
- 27 December 2010
- Published by Wiley in Journal of Neurochemistry
- Vol. 116 (6) , 1077-1087
Open Accessp38 Mitogen‐activated protein kinase and PI3‐kinase are involved in up‐regulation of mu opioid receptor transcription induced by cycloheximide
J. Neurochem. (2011)116, 1077–1087. Despite several decades of efforts to develop safer, efficacious, and non‐addictive opioids for pain treatment, morphine remains the most valuable painkiller in contemporary medicine. Morphine and endogenous mu opioid peptides exert their pharmacological actions mainly through the mu opioid receptor (MOR). Analgesic effects of opioids in animals are dependent on the MOR expression levels, as demonstrated by studies of MOR‐knockout mice (homo/heterozygotes) and MOR‐less expressing mice. Surprisingly, in the course of our investigation to understand the mechanisms involved in the regulation of MOR gene expression, cycloheximide (CHX), a known protein synthesis inhibitor, markedly induced accumulation of MOR mRNAs in both MOR‐negative and ‐positive cells. This induction was blocked by inhibitors of phosphoinositide 3‐kinase (PI3‐K) and p38 MAPK, but not by a p42/44 MAPK inhibitor.In vitro, CHX was found to activate the MOR promoter and this activation was suppressed by inhibition of PI3‐K. The transcriptional activator Sox18 was recruited to the MOR promoter in CHX‐treated cells and this recruitment was also inhibited by the PI3‐K and p38 MAPK inhibitors, Ly294002 and SB203580, respectively. Consistently, acetylation of histone H3 and induction of H3‐K4 methylation were detected while reductions of histone deacetylase 2 binding and H3‐K9 methylation were observed on the promoter. Furthermore, the MOR mRNA accumulation was almost completely inhibited in the presence of actinomycin‐D, indicating that this effect occurs mainly through activation of the transcriptional machinery. These observations suggest that CHX directly induces MOR gene transcription by recruiting the active transcription factor Sox18 to the MOR promoter through PI3‐ and/or p38 MAPK pathways.
- 1 July 2010
- Published by Elsevier in Molecular Pharmacology
- Vol. 78 (1) , 58-68
Up-Regulation of the μ-Opioid Receptor Gene Is Mediated through Chromatin Remodeling and Transcriptional Factors in Differentiated Neuronal Cells
The effects of morphine are mediated mainly through the μ opioid receptor (MOR). Expression of the MOR is up-regulated during neuronal differentiation in P19 embryonal carcinoma cells and epigenetic changes play an important role in MOR up-regulation. This study investigates the basis for differentiation-dependent alterations of MOR chromatin by studying the recruitment or dissociation of several factors to the remodeled chromatin locus. Chromatin immunoprecipitation assays were used to demonstrate the recruitment of the transcriptional activator Sp1 and the chromatin remodeling factors Brg1 and BAF155 to this promoter, as well as the dissociation of repressors [histone deacetylases, mSin3A, Brm, and methyl-CpG-binding protein 2 (MeCP2)]. Histone modifications (acetylation, induction of histone H3-lys4 methylation, and reduction of H3-lys9 methylation) were consistently detected on this promoter. Overexpression of Sp1 strongly enhanced MOR promoter activity, and the histone deacetylase inhibitor trichostatin A also increased promoter activity. In vitro DNA CpG-methylation of the promoter partially blocked binding of the Sp1 factor but induced MeCP2 binding. Coimmunoprecipitation studies also found novel evidence of an endogenous MeCP2 interaction with Sp3 but a weaker interaction with Sp1. Overall, the results suggest that during neuronal differentiation, MeCP2 and DNA methylation mediate remodeling of the MOR promoter by chromatin remodeling factors (Brg1 and BAF155) from a compacted state to a conformation allowing access for transcriptional factors. Subsequent recruitment of the activating transcription factor Sp1 to the remodeled promoter results in MOR up-regulation.
- 1 July 2010
- Published by Elsevier in Molecular Pharmacology
- Vol. 78 (1) , 58-68
Up-Regulation of the μ-Opioid Receptor Gene Is Mediated through Chromatin Remodeling and Transcriptional Factors in Differentiated Neuronal Cells
The effects of morphine are mediated mainly through the μ opioid receptor (MOR). Expression of the MOR is up-regulated during neuronal differentiation in P19 embryonal carcinoma cells and epigenetic changes play an important role in MOR up-regulation. This study investigates the basis for differentiation-dependent alterations of MOR chromatin by studying the recruitment or dissociation of several factors to the remodeled chromatin locus. Chromatin immunoprecipitation assays were used to demonstrate the recruitment of the transcriptional activator Sp1 and the chromatin remodeling factors Brg1 and BAF155 to this promoter, as well as the dissociation of repressors [histone deacetylases, mSin3A, Brm, and methyl-CpG-binding protein 2 (MeCP2)]. Histone modifications (acetylation, induction of histone H3-lys4 methylation, and reduction of H3-lys9 methylation) were consistently detected on this promoter. Overexpression of Sp1 strongly enhanced MOR promoter activity, and the histone deacetylase inhibitor trichostatin A also increased promoter activity. In vitro DNA CpG-methylation of the promoter partially blocked binding of the Sp1 factor but induced MeCP2 binding. Coimmunoprecipitation studies also found novel evidence of an endogenous MeCP2 interaction with Sp3 but a weaker interaction with Sp1. Overall, the results suggest that during neuronal differentiation, MeCP2 and DNA methylation mediate remodeling of the MOR promoter by chromatin remodeling factors (Brg1 and BAF155) from a compacted state to a conformation allowing access for transcriptional factors. Subsequent recruitment of the activating transcription factor Sp1 to the remodeled promoter results in MOR up-regulation.
- Open Access
- 1 September 2009
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 13 (9b) , 3591-3615
Epigenetic programming of μ‐opioid receptor gene in mouse brain is regulated by MeCP2 and brg1 chromatin remodelling factor
The pharmacological action of morphine as a pain medication is mediated primarily through the μ‐opioid receptor (MOR). With few exceptions, MOR is expressed in brain regions where opioid actions take place. The basis for this unique spatial expression of MOR remains undetermined. Recently, we reported that DNA methylation of the MOR promoter plays an important role in regulating MOR in P19 cells. In this study, we show that the differential expression of MOR in microdissected mouse brain regions coincides with DNA methylation and histone modifications. MOR expression could be induced by a demethylating agent or a histone deacetylase inhibitor in MOR‐negative cells, suggesting that the MOR gene can be silenced under epigenetic control. Increases in the in vivo interaction of methyl‐CpG‐binding protein 2 (MeCP2) were observed in the cerebellum, in which the MOR promoter was hypermethylated and MOR expression was the lowest among all brain regions tested. MeCP2 is associated closely with Rett syndrome, a neurodevelopmental disorder. We also established novel evidence for a functional role for MeCP2’s association with the chromatin‐remodelling factor Brg1 and DNA methyltransferase Dnmt1, suggesting a possible role for MeCP2 in chromatin remodelling during MOR gene regulation. We conclude that MOR gene expression is epigenetically programmed in various brain regions and that MeCP2 assists the epigenetic program during DNA methylation and chromatin remodelling of the MOR promoter.
- 1 September 2009
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 13 (9b) , 3591-3615
Open AccessEpigenetic programming of μ‐opioid receptor gene in mouse brain is regulated by MeCP2 and brg1 chromatin remodelling factor
The pharmacological action of morphine as a pain medication is mediated primarily through the μ‐opioid receptor (MOR). With few exceptions, MOR is expressed in brain regions where opioid actions take place. The basis for this unique spatial expression of MOR remains undetermined. Recently, we reported that DNA methylation of the MOR promoter plays an important role in regulating MOR in P19 cells. In this study, we show that the differential expression of MOR in microdissected mouse brain regions coincides with DNA methylation and histone modifications. MOR expression could be induced by a demethylating agent or a histone deacetylase inhibitor in MOR‐negative cells, suggesting that the MOR gene can be silenced under epigenetic control. Increases in the in vivo interaction of methyl‐CpG‐binding protein 2 (MeCP2) were observed in the cerebellum, in which the MOR promoter was hypermethylated and MOR expression was the lowest among all brain regions tested. MeCP2 is associated closely with Rett syndrome, a neurodevelopmental disorder. We also established novel evidence for a functional role for MeCP2’s association with the chromatin‐remodelling factor Brg1 and DNA methyltransferase Dnmt1, suggesting a possible role for MeCP2 in chromatin remodelling during MOR gene regulation. We conclude that MOR gene expression is epigenetically programmed in various brain regions and that MeCP2 assists the epigenetic program during DNA methylation and chromatin remodelling of the MOR promoter.
- 1 July 2007
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 27 (13) , 4720-4736
Evidence of Endogenous Mu Opioid Receptor Regulation by Epigenetic Control of the Promoters
The pharmacological effect of morphine as a painkiller is mediated mainly via the mu opioid receptor (MOR) and is dependent on the number of MORs in the cell surface membrane. While several studies have reported that the MOR gene is regulated by various cis- and trans-acting factors, many questions remain unanswered regarding in vivo regulation. The present study shows that epigenetic silencing and activation of the MOR gene are achieved through coordinated regulation at both the histone and DNA levels. In P19 mouse embryonal carcinoma cells, expression of the MOR was greatly increased after neuronal differentiation. MOR expression could also be induced by a demethylating agent (5′-aza-2′-deoxycytidine) or histone deacetylase inhibitors in the P19 cells, suggesting involvement of DNA methylation and histone deacetylation for MOR gene silencing. Analysis of CpG DNA methylation revealed that the proximal promoter region was unmethylated in differentiated cells compared to its hypermethylation in undifferentiated cells. In contrast, the methylation of other regions was not changed in either cell type. Similar methylation patterns were observed in the mouse brain. In vitro methylation of the MOR promoters suppressed promoter activity in the reporter assay. Upon differentiation, the in vivo interaction of MeCP2 was reduced in the MOR promoter region, coincident with histone modifications that are relevant to active transcription. When MeCP2 was disrupted using MeCP2 small interfering RNA, the endogenous MOR gene was increased. These data suggest that DNA methylation is closely linked to the MeCP2-mediated chromatin structure of the MOR gene. Here, we propose that an epigenetic mechanism consisting of DNA methylation and chromatin modification underlies the cell stage-specific mechanism of MOR gene expression.
- 1 July 2007
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 27 (13) , 4720-4736
Evidence of Endogenous Mu Opioid Receptor Regulation by Epigenetic Control of the Promoters
The pharmacological effect of morphine as a painkiller is mediated mainly via the mu opioid receptor (MOR) and is dependent on the number of MORs in the cell surface membrane. While several studies have reported that the MOR gene is regulated by various cis- and trans-acting factors, many questions remain unanswered regarding in vivo regulation. The present study shows that epigenetic silencing and activation of the MOR gene are achieved through coordinated regulation at both the histone and DNA levels. In P19 mouse embryonal carcinoma cells, expression of the MOR was greatly increased after neuronal differentiation. MOR expression could also be induced by a demethylating agent (5′-aza-2′-deoxycytidine) or histone deacetylase inhibitors in the P19 cells, suggesting involvement of DNA methylation and histone deacetylation for MOR gene silencing. Analysis of CpG DNA methylation revealed that the proximal promoter region was unmethylated in differentiated cells compared to its hypermethylation in undifferentiated cells. In contrast, the methylation of other regions was not changed in either cell type. Similar methylation patterns were observed in the mouse brain. In vitro methylation of the MOR promoters suppressed promoter activity in the reporter assay. Upon differentiation, the in vivo interaction of MeCP2 was reduced in the MOR promoter region, coincident with histone modifications that are relevant to active transcription. When MeCP2 was disrupted using MeCP2 small interfering RNA, the endogenous MOR gene was increased. These data suggest that DNA methylation is closely linked to the MeCP2-mediated chromatin structure of the MOR gene. Here, we propose that an epigenetic mechanism consisting of DNA methylation and chromatin modification underlies the cell stage-specific mechanism of MOR gene expression.
- Open Access
- 1 May 2004
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 279 (19) , 19764-19774
Transcriptional Regulation of Mouse μ Opioid Receptor Gene by PU.1
- 1 May 2004
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 279 (19) , 19764-19774
Open AccessTranscriptional Regulation of Mouse μ Opioid Receptor Gene by PU.1
- Open Access
- 1 February 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (6) , 3742-3750
Mouse μ Opioid Receptor Distal Promoter Transcriptional Regulation by SOX Proteins
- 1 February 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (6) , 3742-3750
Open AccessMouse μ Opioid Receptor Distal Promoter Transcriptional Regulation by SOX Proteins